The emerging role of solifenacin in the treatment of overactive bladder

Expert Opinion on Investigational Drugs

Volumn 13, Issue 10, 2004, Pages 1339-1348

  Robinson, Dudley ^a   Cardozo, Linda ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Antimuscarinics; Detrusor overactivity; Overactive bladder; Solifenacin; Urinary incontinence

Indexed keywords

ESTRADIOL; KETOCONAZOLE; LEVONORGESTREL; MUSCARINIC RECEPTOR BLOCKING AGENT; ORAL CONTRACEPTIVE AGENT; OXYBUTYNIN; SOLIFENACIN; TOLTERODINE;

ANTICHOLINERGIC EFFECT; AREA UNDER THE CURVE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MARKETING; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DRUG TOLERABILITY; ECG ABNORMALITY; EMBRYOTOXICITY; HUMAN; NONHUMAN; OVERACTIVE BLADDER; RECEPTOR BLOCKING; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; VISUAL IMPAIRMENT; XEROSTOMIA;

CLINICAL TRIALS; HUMANS; MUSCARINIC ANTAGONISTS; QUINUCLIDINES; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; URINARY INCONTINENCE;

EID: 5444253913     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.10.1339     Document Type: Review

References (34)

1. STEWART WF, COREY R, HERZOG AR et al.: Prevalence of overactive bladder in women: results from the NOBLE program. Int. Urogynaecol. J. (2001) 12 (3):S66.
2. MILSOM I, ABRAMS P, CARDOZO L, ROBERTS RG, THUROFF J, WEIN AJ: How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study. BJU Int. (2001) 87 (9):760-766.
3. ABRAMS P, CARDOZO L, FALL M, GRIFFITHS D, ROSIER P, ULMSTEN U et al.: The standardisation of terminology of lower urinary tract function. Report from the standardisation committee of the International Continence Society. Neurourol. Urodyn. (2002) 21: 167-178.
4. ANDERSSON K-E: The overactive bladder. Pharmacologic basis of drug treatment. Urology (1997) 50 (6A Suppl.):74-84.
5. CAULFIELD MP, BIRDSALL NJ: International Union of Pharmacology XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. (1998) 50: 279.
6. YAMAGUCHI O, SHISIDA K, TAMURA K et al.: Evaluation of mRNAs encoding muscarinic receptor subtypes in human detrusor muscle. J. Urol. (1996) 156: 1208.
7. 3 receptors coupled to inositol phospholipid hydrolysis in human detrusor cultured smooth muscle cells. J. Urol. (1995) 154: 1241.
8. 3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br. J. Pharmacol. (1997) 120: 1409.
9. HEGDE SS, EGLEN RM: Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci. (1999) 64: 419.
10. 2 receptor contributes to contraction of the denervated rat urinary bladder. Am. J. Physiol. (1998) 275: 1654.
11. IKEDA K: Affinity of YM905 and Oxybutynin for various neurotransmitter receptors and ion channels. Yamanouchi Pharmaceutical Co. Ltd (1998). Registration No. D9801968-1. International Study ID:905-PH-001.
12. IKEDA K: Affinity of YM905 for human muscarinic M1, M2 and M3 receptors. Yamanouchi Pharmaceutical Co. Ltd (1998). Registration No. D199803214-02.00. International Study ID:905-PH-002.
13. SUZUKI M: Inhibitory effect of YM905 on carbachol-induced contraction of guinea pig urinary bladder. Yamanouchi Pharmaceutical Co. Ltd (1998). Registration No. D9803231-1. International Study ID:905-PH-007.
14. IKEDA K, KOBAYASHI S: Effects of YM905, Oxybutynin and Darifenacin on carbachol induced intracellular calcium mobilization by dispersed longitudinal smooth muscle cells of guinea pig colon. Yamanouchi Pharmaceutical Co. Ltd (1998). Registration No. D199803320-02.00. International Study ID:905-PH-006.
15. 2+ mobilization in acutely dissociated cells of guinea pig urinary bladder smooth muscle and murine submandibular gland. Yamanouchi Pharmaceutical Co. Ltd (1998). Registration No. D199803217-02.000. International Study ID:905-PH-005.
16. IKEDA K: Effect of YM905 on response of urinary bladder and salivary gland to carbachol in anesthetised mouse. (1998) Registration No: D199803215-02.00. International Study ID:905-PH-010.
17. SAITOH C, IIZUMI Y. Effect of YM-67905 on micturition reflex in anesthetised rats. Yamanouchi Pharmaceutical Co. Ltd (1998). Registration No. D9802853-1. International Study ID:905-PH-011.
18. IKEDA K: Effect of chronic doses of YM905 on carbachol induced salivary secretion in mice. Yamanouchi Pharmaceutical Co. Ltd (1998). Registration No.D199803318-02.00. International Study ID:905-PH-020.
19. KATZ IR, SANDS LP, BILKER W, DIFILIPPO S, BOYCE A, D'ANGELO K: Identification of medication that cause cognitive impairment in older people: the case of oxybutynin chloride. J. Am. Geriatr. Soc. (1998) 46: 8-13.
20. YANAGIRARA T. Plasma concentrations of the unchanged drug after repeated oral administration of YM905 to dogs. Yamanouchi Pharmaceutical Co. Ltd (1998). Registration No.D9803132-1. International Study ID:905-ME-004.
21. YANAGIHARA T: Plasma concentrations of the unchanged drug and its metabolite BY-348C after single intravenous and oral administration of YM905 to rats. Yamanouchi Pharmaceutical Co. Ltd (1998). Registration No.D9802939-1. International Study ID:905-ME-002.
22. YANAGIRARA T: Plasma concentrations of the unchanged drug after single intravenous and oral administration of YM905 in dogs. Yamanouchi Pharmaceutical Co. Ltd (1998). Registration No.D9802940-1. International Study ID:905-ME-003.
23. YANAGIHARA T: In vitro plasma protein binding of YM905. Yamanouchi Pharmaceutical Co Ltd (1998). Registration No. D199803314-02.00. International study ID:905-ME-007.
24. YANAGIHARA T:Comparison of in vitro metabolic patterns of YM905 among various species. Yamanouchi Pharmaceutical Co Ltd (1998). Registration No.D9803351-1. International study ID:905-ME-009.
25. ONDERWATER RCA: Identification of human liver CYP isoforms involved in the metabolism of YM905. Yamanouchi Europe BV. (1999) Registration No: D199900072-01.00 International Study ID:905-ME-020.
26. 14C-YM905 to rats. Yamanouchi Pharmaceutical Co Ltd (1997) Registration No: D9802237-1 International Study ID:905-ME-001.
27. CHAPPLE CR, ARANO P, BOSCH JL, DE RIDDER D, KRAMER AE, RIDDER AM: Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled Phase 2 dose-finding study. BJU Int. (2004) 93 (1):71-77.
28. CHAPPLE CR, RECHBERGER T, AL-SHUKRI S et al.: Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. (2004) 93 (3):303-310.
29. VAN APLEN WW: A double blind, randomised, placebo controlled dose rising study in healthy male volunteers to evaluate safety, tolerability and pharmacokinetics of multiple dosing with YM905. YEU. (1998) Registration No. D9801421-1. International Study ID:905-CL-002.
30. FUDER H: A double blind, randomised, placebo controlled rising study in elderly male and female volunteers to evaluate safety, tolerability and pharmacokinetics of multiple dosing with YM905. Yumanouchi Europe BV. Registration No: D9803294-1. International Study ID:905-CL-004.
31. VAN APLEN WW: A placebo controlled dose rising study in healthy male volunteers to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of single oral dosages of YM905. Clinical Pharmacology Research Department, Yamanouchi Europe BV. (1998). Registration No: D200001570-01.00. International Study ID:905-CL-001.
32. DIXON RM: Effect of multiple doses of ketoconazole on the pharmacokinetics of a single dose of YM905 administered orally in healthy male and female volunteers. Covance Clinical Research Unit, Inc. (2001). International Study ID:905-CL-010.
33. HEGER-MAHN D: A double-blind, placebo controlled, cross over pharmacokinetic interaction of steady state YM905 and steady state oral contraceptive in healthy female volunteers. Yamanouchi Europe BV. International Study ID:905-CL-011.
34. KELLEHER CJ, CARDOZO LD, KHULLAR V, SALVATORE S: A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br. J. Obstet. Gynaecol. (1997) 104: 988-993